STF-118804
CAS No. 894187-61-2
STF-118804( STF118804 | STF 118804 )
Catalog No. M17646 CAS No. 894187-61-2
STF-118804 is a highly specific NAMPT inhibitor; reduces the viability of most B-ALL cell lines with IC50 <10 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 50 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 46 | In Stock |
|
| 10MG | 70 | In Stock |
|
| 25MG | 148 | In Stock |
|
| 50MG | 237 | In Stock |
|
| 100MG | 352 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSTF-118804
-
NoteResearch use only, not for human use.
-
Brief DescriptionSTF-118804 is a highly specific NAMPT inhibitor; reduces the viability of most B-ALL cell lines with IC50 <10 nM.
-
DescriptionSTF-118804 is a potent and highly specific NAMPT inhibitor ( nicotinamide phosphoribosyl transferase inhibitor), which improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia, and targets leukemia stem cells.
-
In Vitro——
-
In Vivo——
-
SynonymsSTF118804 | STF 118804
-
PathwayOthers
-
TargetOther Targets
-
RecptorNAMPT
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number894187-61-2
-
Formula Weight461.53
-
Molecular FormulaC25H23N3O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 31 mg/mL; 67.17 mM
-
SMILESCc1ccc(cc1)S(=O)(=O)Cc1c(oc(n1)c1ccc(cc1)C(=O)NCc1cnccc1)C
-
Chemical Name4-(5-methyl-4-(tosylmethyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
p2Ca
p2Ca, a naturally processed peptide that derives from a ubiquitous enzyme, alpha-ketoglutarate dehydrogenase, and is recognized in association with the class I MHC protein, Ld, by a CTL clone (2C).
-
Luxdegalutamide
Luxdegalutamide (ARV-766) is a novel, potent, and orally bioavailable proteolytic targeting chimera (PROTAC) protein degrader that degrades not only wild-type AR but also clinically relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.
-
TT01001
TT01001 is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 can be used in studies about the treatment of type II diabetes.
Cart
sales@molnova.com